AstraZeneca stock weighs reported 10 billion US dollar Rhythm bid
Published on 11/06/2026 at 17:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRhythm Bid Adds Rare Disease Focus
- A reported non-binding proposal would broaden Alexion's rare-disease portfolio into rare forms of obesity.
- The reported consideration includes milestone payments, leaving the final price and transaction outcome uncertain.
- Further negotiations, shareholder approvals and regulatory steps would be needed before a deal could close.
AstraZeneca is reportedly pursuing a non-binding proposal for Rhythm Pharmaceuticals, according to a report carried by The Manila Times on Friday, November 6. The report said the approach was made last month and could value Rhythm at about 10 billion US dollars, with milestone payments included.
AstraZeneca stock traded at 166.60 euros on Lang & Schwarz at 17:03 CET on Friday, November 6, 2026. That was 2.11 percent above the 163.15-euro quote at 10:04 CET in the preceding report on the same day.
The reported proposal would be pursued through Alexion, AstraZeneca's rare-disease business. AstraZeneca acquired Alexion for 39 billion US dollars in 2021 as it sought to expand beyond oncology and broader biopharmaceutical operations.
Rare Disease Strategy Comes Into Focus
Rhythm develops treatments for rare neuroendocrine and metabolic disorders, including severe obesity. Its Imcivree treatment received expanded US approval in March for a rare form of obesity caused by brain damage, giving Rhythm a commercial position in a specialized segment rather than the broader weight-loss market.
The reported proposal offered 124 US dollars per Rhythm share last month and could reach 134 US dollars when milestone payments are included. The reports do not establish a signed transaction, a final price or the conditions governing those payments.
Rhythm shares closed 28 percent higher at 110.68 US dollars on November 4 after the proposal was reported, according to The Manila Times. AstraZeneca and Rhythm had not confirmed a transaction in the report, leaving negotiations, possible competing bids and regulatory review as key next steps.
Investors can follow the real-time quote of AstraZeneca stock.
AstraZeneca Company Facts
- Company: AstraZeneca plc
- ISIN: GB0009895292
- Lang & Schwarz quote: 166.60 euros at 17:03 CET on November 6, 2026
- Reported proposal: About 10 billion US dollars for Rhythm Pharmaceuticals
- Reported share consideration: 124 US dollars, potentially up to 134 US dollars including milestones
The FTSE 100 is the relevant UK market backdrop for AstraZeneca investors; see current market reports.
